212 related articles for article (PubMed ID: 9122472)
1. [Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions].
Maurea S; Mainolfi C; Wang H; Varrella P; Panico MR; Klain M; Rossi R; Cremona F; Bazzicalupo L; Salvatore M
Radiol Med; 1996 Dec; 92(6):782-7. PubMed ID: 9122472
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
[TBL] [Abstract][Full Text] [Related]
3. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions.
Maurea S; Mainolfi C; Bazzicalupo L; Panico MR; Imparato C; Alfano B; Ziviello M; Salvatore M
AJR Am J Roentgenol; 1999 Jul; 173(1):25-9. PubMed ID: 10397094
[TBL] [Abstract][Full Text] [Related]
4. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Boland GW; Goldberg MA; Lee MJ; Mayo-Smith WW; Dixon J; McNicholas MM; Mueller PR
Radiology; 1995 Jan; 194(1):131-4. PubMed ID: 7997539
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses.
Maurea S; Klain M; Mainolfi C; Ziviello M; Salvatore M
J Nucl Med; 2001 Jun; 42(6):884-92. PubMed ID: 11390552
[TBL] [Abstract][Full Text] [Related]
6. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques.
Maurea S; Caracò C; Klain M; Mainolfi C; Salvatore M
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):188-97. PubMed ID: 15499292
[TBL] [Abstract][Full Text] [Related]
7. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience.
Blake MA; Slattery JM; Kalra MK; Halpern EF; Fischman AJ; Mueller PR; Boland GW
Radiology; 2006 Mar; 238(3):970-7. PubMed ID: 16505394
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
9. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
[TBL] [Abstract][Full Text] [Related]
10. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG.
Minn H; Salonen A; Friberg J; Roivainen A; Viljanen T; Långsjö J; Salmi J; Välimäki M; Någren K; Nuutila P
J Nucl Med; 2004 Jun; 45(6):972-9. PubMed ID: 15181132
[TBL] [Abstract][Full Text] [Related]
11. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
12. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.
Patz EF; Lowe VJ; Hoffman JM; Paine SS; Burrowes P; Coleman RE; Goodman PC
Radiology; 1993 Aug; 188(2):487-90. PubMed ID: 8327702
[TBL] [Abstract][Full Text] [Related]
13. CT and
Altinmakas E; Üçışık-Keser FE; Medeiros LJ; Ng CS
Acad Radiol; 2019 Jun; 26(6):e108-e114. PubMed ID: 30076085
[TBL] [Abstract][Full Text] [Related]
14. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
[TBL] [Abstract][Full Text] [Related]
15. Characterization of chest masses by FDG positron emission tomography.
Hübner KF; Buonocore E; Singh SK; Gould HR; Cotten DW
Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer.
Kumar R; Xiu Y; Yu JQ; Takalkar A; El-Haddad G; Potenta S; Kung J; Zhuang H; Alavi A
J Nucl Med; 2004 Dec; 45(12):2058-62. PubMed ID: 15585482
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography of thyroid masses.
Adler LP; Bloom AD
Thyroid; 1993; 3(3):195-200. PubMed ID: 8257858
[TBL] [Abstract][Full Text] [Related]
18. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.
Lowe VJ; DeLong DM; Hoffman JM; Coleman RE
J Nucl Med; 1995 May; 36(5):883-7. PubMed ID: 7738668
[TBL] [Abstract][Full Text] [Related]
19. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
20. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
